December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Influence of Brimonidine (alpha-2 agonist) and Nitroxide Ester (ETOPS) on Retinal Cell Survival Following Apoptotic Stimulus
Author Affiliations & Notes
  • MM Cruz
    Doheny Eye Institute Keck School of Medicine USC Los Angeles CA
  • S Ornelas Walker
    Doheny Eye Institute Keck School of Medicine USC Los Angeles CA
  • KP Kolostyak
    Doheny Eye Institute Keck School of Medicine USC Los Angeles CA
  • FN Ross-Cisneros
    Doheny Eye Institute Keck School of Medicine USC Los Angeles CA
  • J Sebag
    Doheny Eye Institute Keck School of Medicine USC Los Angeles CA
  • CJ C Hsia
    SynZyme Technologies LLC Irvine CA
  • AA Sadun
    Doheny Eye Institute Keck School of Medicine USC Los Angeles CA
  • Footnotes
    Commercial Relationships    M.M. Cruz, Merck & Co. F; S. Ornelas Walker, Merck & Co. F; K.P. Kolostyak, Merck & Co. F; F.N. Ross-Cisneros, Merck & Co. F; J. Sebag, SynZyme Technologies LLC C; C.J.C. Hsia, SynZyme Technologies LLC E, P; A.A. Sadun, Merck & Co. F; SynZyme Technologies LLC F, C. Grant Identification: Merck & Company, Synzyme Corporation, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 766. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      MM Cruz, S Ornelas Walker, KP Kolostyak, FN Ross-Cisneros, J Sebag, CJ C Hsia, AA Sadun; Influence of Brimonidine (alpha-2 agonist) and Nitroxide Ester (ETOPS) on Retinal Cell Survival Following Apoptotic Stimulus . Invest. Ophthalmol. Vis. Sci. 2002;43(13):766.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare purported neuroprotective agents in their ability to rescue human retinoblastoma cells undergoing apoptosis induced by TNF-alpha in vitro. Pentoxifylline, dizocilipine (MK-801), 3-aminobenzamide (3-ABA), Brimonidine, and TOPS-ester (ethyl-2,2',6,6'-tetramethylpiperidylidene-1-oxyl-succinate, or "ETOPS") were evaluated. Brimonidine is a selective alpha-2 agonist which has been reported to increase growth factor expression and apoptosis cascade inhibition, while ETOPS has been reported to decrease reactive oxygen species toxicity in several challenge systems. Methods: Degrees of apoptosis detected via annexin V fluorescent apoptosis cytometry were compared over a 24 hour period to assess the relative neuroprotective efficacy between the representative agents, brimonidine and ETOPS. Y-79 and WERI-Rb-1 human retinoblastoma cells (≷10E6/ml) were aliquoted into separate culture plates with the putative neuroprotective agents in the presence and absence of TNF-alpha (0.5ng/ml). Brimonidine (10uM) and ETOPS (2mM) were referenced against pentoxifylline (25ug/ml), MK-801 (10uM), and 3-ABA (10mM). FL1/FL2 plots were compensated for necrosis to identify true apoptotic populations. Results: 24 hour studies showed brimonidine retarded cell death about two and a half fold, as compared to cytokine-treated positive controls. ETOPS treated samples exhibited an approximate four-fold decrease in cell death, as compared to TNF-positive controls. Conclusions: Brimonidine is effective in ameliorating cell death induced by TNF-alpha, a primary inflammatory cytokine detected in many neurodegenerative diseases of the CNS. To an even greater degree, ETOPS, a novel caged nitroxide, was effective in preventing retinal cell death. Albeit by different mechanisms of action, each of these agents may prove to be effective in minimizing retinal damage if used early.

Keywords: 489 neuroprotection • 323 apoptosis/cell death • 413 flow cytometry 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×